Key facts
- PreludeDx’s last known valuation is $109.3M (Feb 2022).
- It has raised $63.0M; the latest was Later Stage VC ($5.0M) in Nov 2025.
- Notable investors include BlueStone Venture Partners, Evidity Health Capital, Fjord Ventures, National Cancer Institute.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for PreludeDx
- ·The full record, as it builds
Funding rounds
No funding rounds for PreludeDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PreludeDx
Developer of decision-making, actionable tools designed to detect early-stage breast cancer. The company's platform combines proteomic analysis with artificial intelligence to assess recurrence risk and predict radiation therapy benefits to personalize treatment decisions for breast cancer patients, enabling oncologists to tailor interventions, potentially reducing unnecessary treatments and associated side effects.
- Sector
- Healthcare
- HQ
- Laguna Hills, CA, United States
- Founded
- 2009
- Employees
- 49
- Website
- preludedx.com/
- Ownership
- Privately Held (backing)
PreludeDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PreludeDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PreludeDx in its N-PORT filings yet. We sweep new filings monthly.